CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New oral testosterone regimen shows promise in advanced prostate cancer trial
Disease control CompletedThis study tested a new way to give testosterone therapy to men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. Instead of injections, patients took oral testosterone for seven days, then stopped for seven days, repeating this cycle. I…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
New drug combo shows promise for Hard-to-Treat prostate cancer
Disease control CompletedThis study tested a combination of two drugs, talazoparib and temozolomide, in 16 men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The goal was to find the safest dose and see if the drugs could shrink tumors. The treatment is not a cur…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Can testosterone waves help fight resistant prostate cancer?
Disease control CompletedThis early-phase study tested a new treatment schedule for men with castration-resistant prostate cancer. The approach alternates between giving testosterone through the skin and the drug enzalutamide. The main goal was to see if this treatment plan is practical and safe. Thirty …
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
Targeted chemo shows promise for tough prostate cancer
Disease control CompletedThis study tested the chemotherapy drug carboplatin in 16 men with advanced prostate cancer that no longer responds to hormone therapy. The cancer had specific gene changes that might make it sensitive to this treatment. The goal was to see if carboplatin could shrink tumors or l…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
New radioactive cocktail shows promise for tough prostate cancers
Disease control CompletedThis study tested a radioactive drug (I-131-1095) plus a standard hormone therapy (enzalutamide) in 120 men with advanced prostate cancer that had stopped responding to another treatment (abiraterone). The goal was to see if the combination could shrink tumors and lower PSA level…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Progenics Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 05, 2026 11:54 UTC
-
New steroid shot may delay chemo in tough prostate cancer
Disease control CompletedThis study tested a steroid called triamcinolone, given as a shot, in 55 men with castration resistant prostate cancer (cancer that no longer responds to standard hormone therapy). The goal was to see if it could control the cancer longer than current steroid pills, which typical…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Barts & The London NHS Trust • Aim: Disease control
Last updated May 04, 2026 16:23 UTC